Cantargia R&D Day on nadunolimab
About The Event
Join us for the Cantargia R&D Day, featuring presentations from two renowned oncology experts. Prof Eric Van Cutsem, MD, PhD (University Hospitals Gasthuisberg/Leuven & KU Leuven) and Dr Luis Paz-Ares (Hospital Doce de Octubre/National Oncology Research Center/President Oncosur Foundation) will discuss the current treatment landscape and unmet medical need in treating patients with pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) respectively
Prof Van Cutsem and Dr Paz-Ares will also discuss data presented at ASCO 2022 on Cantargia’s lead asset nadunolimab in PDAC and NSCLC, respectively. Cantargia’s leadership team will then provide a pipeline update in the light of this new data, including a review of the next development steps for nadunolimab.
Nadunolimab is a first-in-class antibody targeting IL1RAP, currently being evaluated with standard of care chemotherapy or checkpoint inhibitor in 5 phase I/II clinical trials with a primary focus on NSCLC and PDAC. Nadunolimab will also be investigated in a phase II/III trial in pancreatic cancer in collaboration with the US network PanCAN starting in H2 2022. Nadunolimab induces ADCC and blocks signaling of both IL-1α and IL-1β, thereby counteracting the contribution of IL-1 to the immune suppressive tumor microenvironment and development of resistance to chemotherapy.
A live question and answer session will follow each presentation.